Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania
2006

Drug Resistance in Malaria Treatment in Tanzania

Sample size: 141 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mbugi Erasto V, Mutayoba Benezeth M, Malisa Allen L, Balthazary Sakurani T, Nyambo Thomas B, Mshinda Hassan

Primary Institution: Sokoine University of Agriculture

Hypothesis

What is the frequency of drug resistance mutations in Plasmodium falciparum among children treated with sulphadoxine-pyrimethamine in Tanzania?

Conclusion

The study found high levels of drug resistance mutations in malaria parasites, indicating a need to reconsider the use of sulphadoxine-pyrimethamine as a first-line treatment.

Supporting Evidence

  • 89.4% of children showed adequate clinical response at day 14 after treatment.
  • High proportions of mutations were found in the dhfr and dhps genes.
  • Treatment failures were observed in 10.6% of the patients.

Takeaway

This study looked at how well a malaria treatment works in kids and found that many of the parasites are becoming resistant to the medicine.

Methodology

The study used PCR and RFLP to analyze mutations in the dhfr and dhps genes associated with drug resistance in blood samples from children.

Limitations

The study was limited by the exclusion of patients who did not complete the follow-up and the potential for confounding factors affecting treatment outcomes.

Participant Demographics

Children aged less than 5 years from Mlimba division, Kilombero district, Tanzania.

Digital Object Identifier (DOI)

10.1186/1475-2875-5-94

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication